Ingredients, regulation, launches, trends, and AI in beauty — analyzed, not amplified.
Head-to-head data is finally landing for retinaldehyde. Here's what's holding up — and what isn't.
The FDA is reviewing topical exosome claims. Brands and dermatology offices alike are bracing.
Which peptide combos have human data, which are lab-only, and which are just a sticker.
Bemotrizinol may finally cross the FDA finish line. What it changes for American shoppers.
Most cases involve misuse, but device standards still vary.